Biologic psoriasis treatment has evolved rapidly over the last two decades, intensifying competition in the pharmaceutical industry. With continuous innovation, companies face an ever-growing need for strategic adaptation to maintain market position.

Ipsos' Dermatology RepInsight study provides critical visibility into pharmaceutical sales representative-dermatologist interactions. This pioneering methodology captures real-time feedback after sales meetings, tracking how prescriber perceptions and behaviours evolve regarding key psoriasis treatments.

The study combines quantitative metrics with qualitative insights-including voice recordings and sales materials analysis-to evaluate competitive positioning and messaging effectiveness. This approach delivers actionable intelligence that enables companies to optimise marketing strategies, refine sales communications, implement rapid salesforce enhancements, and ultimately improve patient care.

With its rapid, in-depth analysis of treatment decision factors, Ipsos' Syndicated Dermatology RepInsight study becomes essential for pharmaceutical companies seeking to gain competitive advantage in the increasingly complex psoriasis treatment landscape.